Phaseline

Companies › DiaMedica Therapeutics

DiaMedica Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DM199
Recombinant human tissue kallikrein (rinvecalinase alfa) - serine protease that activates
KLKB1Phase 2Acute StrokeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05065216DM199Phase 2Acute StrokeNeurologyDec 2026

From the company's SEC filings

Cash and short-term investments of $44m on 2026-06-30; operating cash outflow about $35m a year; runway about 15 months at that burn, to Sep 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

KLKB1 (1)

Companies with the same targets

Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands

Companies built like this

Satellos Bioscience Coya Therapeutics PepGen Cognition Therapeutics IGC Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.